Translation of tissue-engineering innovations requires a connected ecosystem

The potential of tissue engineering to deliver clinical advances hinges on a connected ecosystem that includes academics, funding agencies, entrepreneurs, investors, the pharmaceutical industry and regulatory bodies. Open dialog on goals and risks across these stakeholders is key to implementing bioengineered tissue models in drug development and tissue therapies.